AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37403057
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (ST)
Trial: 36305459
Drug: Peripheral venous
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral venous access in active treatment groups
Trial: 34905446
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (dose 1) and MMR on d 0 and EV71 vaccine (dose 2) and LA‐JEV on d 30 (Group 1)
Trial: 34905446
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of doses 1 and 2 of EV71 vaccine on d 0 and 30, respectively (Group 3)
Trial: 32960998
Drug: eDiary documentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eDiary documentation of bowel movements and fecal incontinence episodes, prompted by twice-daily phone notifications, with adherence rates of 95% and notifications prompting 29.6% of entries.
Trial: 32487163
Drug: multimodal hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multimodal hand therapy
Trial: 32487163
Drug: combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination therapy with both hand therapy and ultrasound therapy
Trial: 34396816
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 100% lavender essential oil
Trial: 35745231
Drug: Nutraceutical supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical supplements (omega‐3 fatty acids, anthocyanins, and alpha‐cyclodextrins) for 12 weeks
Trial: 33631287
Drug: Soluble interleukin-6
RxNorm normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble interleukin-6 receptor (sIL-6R)
Trial: 32475634
Drug: Modern radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modern radiotherapy delivery systems and treatment strategies
Trial: 34806342
Drug: HCQ monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ monotherapy
Trial: 33506858
Drug: Nudge (providing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nudge (providing a paper form for free vaccine delivery and contacts for occupational health services)
Trial: 32799356
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics
Trial: 34279976
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management
Trial: 36251060
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FA, tNAA/tCr, NSE, motor score, and Epileptic Seizures (ES)
Trial: 33993473
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (1.0 mg/kg/h after a loading dose of 0.3 mg/kg)
Trial: 34318757
Drug: Standard-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT
Trial: 39481395
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg
Trial: 36412328
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.25% plain bupivacaine
Trial: 37160401
Drug: Anticholinergic drugs
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drugs
Trial: 34551104
Drug: Low-dose vaccine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaccine
Trial: 36207894
Drug: Medium-dose vaccine
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose vaccine
Trial: 37584344
Drug: High-dose vaccine
RxNorm normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vaccine
Trial: 32994466
Drug: Belotecan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belotecan 0.5 mg/m2 for five consecutive days every 3 weeks
Trial: 32994466
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 for five consecutive days every 3 weeks
Trial: 34263581
Drug: Remimazolam 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam 0.2 mg/kg (R1 group)
Trial: 34263581
Drug: Remimazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam 0.3 mg/kg (R2 group)
Trial: 34263581
Drug: Remimazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remimazolam 0.4 mg/kg (R3 group)
Trial: 36630619
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy
Trial: 32057103
Drug: Fluorescence cholangiography
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence cholangiography using 0.05 mg/kg indocyanine green
Trial: 33278671
Drug: Metformin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin group
Trial: 34080572
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dapoxetine (Group 2)
Trial: 35573309
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU intranasal oxytocin
Trial: 35908275
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 400 mg, 800 mg, or 1200 mg QD
Trial: 38662318
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine (RZV)
Trial: 32744380
Drug: janagliflozin 25
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: janagliflozin 25 mg
Trial: 32744380
Drug: janagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: janagliflozin 50 mg
Trial: 36130222
Drug: Whole almonds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole almonds (56 g/d)
Trial: 35911237
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy with Acceptance and Commitment Therapy (CBT-ACT)
Trial: 32702570
Drug: Durvalumab 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 10 mg/kg every 2 weeks
Trial: 35076832
Drug: Parent–Child Interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent–Child Interaction Therapy (PCIT)
Trial: 38042525
Drug: Osimertinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib monotherapy
Trial: 36184253
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (200 μg/day)
Trial: 33499521
Drug: Phototherapy kiosk
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phototherapy kiosk (PK) treatments for 10 weeks
Trial: 36077723
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg/day
Trial: 32639484
Drug: Untreated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated group (no treatment)
Trial: 34476464
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) for depression over 2 months
Trial: 35398399
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy (PST) for depression
Trial: 37786451
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg
Trial: 37786451
Drug: Tocilizumab 4
RxNorm normalized name: tocilizumab 400 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 4 mg/kg
Trial: 33199491
Drug: Genomically directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomically directed therapy
Trial: 34220720
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein (15 g)
Trial: 34220720
Drug: Placebo (water,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (water, 100 ml)
Trial: 35980261
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide (4-6 µg/kg)
Trial: 35980261
Drug: Glycopyrronium bromide
RxNorm normalized name: Glycopyrronium bromide
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium bromide (4 µg/kg)
Trial: 33410336
Drug: Brief Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive Behavioral Therapy for Insomnia (bCBTi) - four weekly sessions
Trial: 32401718
Drug: Platelet rich
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma intradermal injections
Trial: 35003725
Drug: One-time combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time combination cefazolin 2 g and metronidazole 500 mg preoperatively
Trial: 35003725
Drug: Tinzaparin 4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin 4500 units SC daily for at least 7 days after discharge
Trial: 33157325
Drug: Open flap
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open flap debridement (OFD) + adjunctive photodynamic therapy (PDT)
Trial: 39377226
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine
Trial: 39566128
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment
Trial: 35603652
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC)
Trial: 37522226
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg
Trial: 39182330
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy
Trial: 33862589
Drug: Flexyn2a vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexyn2a vaccine (10 µg)
Trial: 35175316
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1‐14 every 3 weeks) plus best supportive care (BSC)
Trial: 37814832
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance therapy
Trial: 35763213
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral 600 IU vitamin D supplementation
Trial: 33156757
Drug: Empirical TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical TB treatment
Trial: 39122650
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/day
Trial: 36053934
Drug: Attention-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-based cognitive behavioral treatment (nine weekly sessions)
Trial: 39059373
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream
Trial: 36413080
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg
Trial: 32093742
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) monotherapy at a dosage of 0.05-0.1 mg/kg/day for 6 months
Trial: 33765241
Drug: Outpatient Acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient Acceptance and Commitment Therapy (O‐ACT)
Trial: 32173882
Drug: Single-plane MFU-V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-plane MFU-V treatment (4.5 mm)
Trial: 32173882
Drug: Dual-plane MFU-V
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-plane MFU-V treatment (4.5 and 3.0 mm)
Trial: 33780315
Drug: Straight and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight and slow injection
Trial: 33780315
Drug: Tunneled and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tunneled and fast injection
Trial: 33780315
Drug: Tunneled and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tunneled and slow injection
Trial: 35012439
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive stimulation (iCS) - 47 weekly sessions
Trial: 35012439
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - maintained baseline treatments
Trial: 37265385
Drug: rhTNK-tPA (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTNK-tPA (16 mg intravenous bolus)
Trial: 34251536
Drug: TTO NE
RxNorm normalized name: Ne
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTO NE + ADA Gel
Trial: 34251536
Drug: ADA Marketed
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA Marketed Gel
Trial: 34543460
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in pristine bone (CT)
Trial: 35259925
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system blockers
Trial: 35051663
Drug: aPDT (antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT (antimicrobial photodynamic therapy) using a curcumin-based photosensitizer, exposed to 660 nm light for 5 minutes at 200 J/cm2 fluency.
Trial: 35333743
Drug: Trazodone (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (9 to 12 mg/kg)
Trial: 34534319
Drug: Preseason HAI
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseason HAI antibody titers
Trial: 35871010
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) with pre-treatment assessment interview
Trial: 32472526
Drug: Antiplatelet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet and anticoagulant therapies
Trial: 35643967
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol maleate 0.5%
Trial: 35678032
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE) 300 mg with fexofenadine 60 mg and pseudoephedrine 120 mg
Trial: 35678032
Drug: Water (control)
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control) with fexofenadine 60 mg and pseudoephedrine 120 mg
Trial: 32901235
Drug: Paracetamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (15 mg/kg)
Trial: 33220090
Drug: Transcrestal sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcrestal sinus floor elevation (TSFE) with bovine‐derived xenograft and implant placement
Trial: 33220090
Drug: Lateral sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral sinus floor elevation (LSFE) with bovine‐derived xenograft and implant placement
Trial: 36495879
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 5.4 mg/kg
Trial: 36471429
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral administration of cephalexin and metronidazole
Trial: 32274746
Drug: Scoring balloon
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scoring balloon angioplasty (SBA) prior to drug-coated balloon angioplasty (DCB)
Trial: 33207242
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) combined with the same language treatment
Trial: 32215674
Drug: r-ESWT (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-ESWT (2000 pulses of shockwave at 2.0 to 3.0 bar weekly for three weeks)
Trial: 32470486
Drug: Ruxolitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib plus standard-of-care treatment
Trial: 32470486
Drug: Placebo based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo based on standard-of-care treatment
Trial: 37316311
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches
Trial: 36190739
Drug: All agents
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All agents
Trial: 36400597
Drug: Flutamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (125 mg orally daily)
Trial: 34313697
Drug: Systemic hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Systemic hydrocortisone treatment initiated 7 to 14 days after birth
Trial: 32217498
Drug: Tablet-based TSN
RxNorm normalized name: TSN-084
DrugBank: TSN-084 (DB18306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based TSN app prototype
Trial: 33144157
Drug: Higher adiponectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher adiponectin levels (per 5-µg/ml increase)
Trial: 35807858
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of carbonated water plus two kiwifruit (intervention)
Trial: 35807858
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of carbonated water (control)
Trial: 32538550
Drug: Standard‐of‐care basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐of‐care basal insulin analogues (SOC‐BI)
Trial: 35504634
Drug: Temporary interruption
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary interruption of low-dose methotrexate treatment
Trial: 35504634
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (continuing low-dose methotrexate treatment)
Trial: 33065060
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg)
Trial: 91276441
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg twice a day for three weeks)
Trial: 36401662
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (70 mL, 6.4 mmol NO3−)
Trial: 33377959
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy
Trial: 34898074
Drug: Luobufukebiri Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luobufukebiri Pills (LP), 10 pills bid for 12 weeks
Trial: 34898074
Drug: Luobufukebiri Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luobufukebiri Pills (LP) vs Vitamin E soft capsules
Trial: 35717146
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (90-minute weekly sessions for 6 weeks plus two booster sessions)
Trial: 33051264
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone
Trial: 36055329
Drug: Short treatment
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short treatment with a carbapenem
Trial: 36055329
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment with a carbapenem